Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

RxSight (RXST) EBITDA (2020 - 2025)

RxSight's EBITDA history spans 6 years, with the latest figure at -$9.2 million for Q4 2025.

  • For Q4 2025, EBITDA fell 45.56% year-over-year to -$9.2 million; the TTM value through Dec 2025 reached -$39.1 million, down 43.15%, while the annual FY2025 figure was -$39.1 million, 43.15% down from the prior year.
  • EBITDA reached -$9.2 million in Q4 2025 per RXST's latest filing, up from -$9.6 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of -$5.7 million in Q3 2024 to a low of -$17.7 million in Q1 2022.
  • Average EBITDA over 5 years is -$11.5 million, with a median of -$12.2 million recorded in 2023.
  • Peak YoY movement for EBITDA: plummeted 159.87% in 2021, then skyrocketed 55.7% in 2024.
  • A 5-year view of EBITDA shows it stood at -$15.7 million in 2021, then rose by 1.12% to -$15.6 million in 2022, then soared by 41.4% to -$9.1 million in 2023, then soared by 31.01% to -$6.3 million in 2024, then plummeted by 45.56% to -$9.2 million in 2025.
  • Per Business Quant, the three most recent readings for RXST's EBITDA are -$9.2 million (Q4 2025), -$9.6 million (Q3 2025), and -$11.9 million (Q2 2025).